NBI 74788

Drug Profile

NBI 74788

Alternative Names: NBI-74788

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurocrine Biosciences
  • Class Peptides
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Congenital adrenal hyperplasia

Most Recent Events

  • 03 Aug 2017 Neurocrine Biosciences plans a phase II trial for classic 21-hydroxylase deficiency Congenital adrenal hyperplasia in November 2017
  • 03 Aug 2017 Neurocrine Biosciences completes a phase I trial in Healthy volunteers in USA
  • 31 Mar 2017 Phase-I clinical trials in Congenital adrenal hyperplasia (In volunteers) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top